Eiger BioPharmaceuticals, Inc. (EIGR)

NASDAQ: EIGR · IEX Real-Time Price · USD
6.24
+0.14 (2.30%)
Jun 24, 2022 4:00 PM EDT - Market closed
2.30%
Market Cap 269.67M
Revenue (ttm) 11.17M
Net Income (ttm) -85.81M
Shares Out 43.22M
EPS (ttm) -2.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,000,770
Open 6.15
Previous Close 6.10
Day's Range 6.14 - 6.49
52-Week Range 3.53 - 10.02
Beta 1.57
Analysts Strong Buy
Price Target 32.64 (+423.1%)
Earnings Date Aug 4, 2022

About EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the tre... [Read more...]

Industry Biotechnology
CEO Krisztina Zsebo
Employees 43
Stock Exchange NASDAQ
Ticker Symbol EIGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for EIGR stock is "Strong Buy." The 12-month stock price forecast is 32.64, which is an increase of 423.08% from the latest price.

Price Target
$32.64
(423.08% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric...

-  Data presented in oral presentation at ENDO 2022 on June 11 -  Avexitide significantly reduced the number of hypoglycemia events and the amount of time spent in hypoglycemia -  Study included patient...

Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EAS...

-  Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus PALO ALTO, Calif. , June 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopha...

Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital...

Eiger nets approximately $11M after retiring its existing debt facility Immediately bolsters cash position and provides access to an additional $35M in non-dilutive capital on clinical and regulatory mi...

Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference

PALO ALTO, Calif. , June 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat a...

Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processi...

If authorized, Zokinvy® (lonafarnib) will be the first and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies - collectively...

Eiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment Conference

PALO ALTO, Calif , May 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat an...

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zo...

PALO ALTO, Calif. and OSAKA, Japan , May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceuticals Inc. ("Eiger", Nasdaq: EIGR) and AnGes Inc. ("AnGes", TYO: 4563) today announced that the companies entered int...

Eiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End Zokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022...

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif. , April 29, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat...

Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and ...

-  Phase 2 study demonstrating avexitide significantly reduced hypoglycemia in children with congenital hyperinsulinism published in Diabetes Care -  Eiger plans to initiate avexitide Phase 3 registrati...

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thur...

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused...

Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments

Chris Kurtz Appointed Chief Technical Officer Sarah Mathieson Appointed Senior Vice President, Corporate Affairs PALO ALTO, Calif. , April 18, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq...

Why Eiger BioPharmaceuticals Stock Is Jumping Today

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to seve...

Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predom...

Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-relat...

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda fo...

Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical...

How Much Upside is Left in Eiger BioPharma (EIGR)? Wall Street Analysts Think 493%

The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the p...

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

PALO ALTO, Calif., March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in March 2022 Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 Phase 3 HDV LIMT-2...

Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business U...

PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat an...

Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and...

Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and...

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patie...

PALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat an...

Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambd...

PALO ALTO, Calif., Dec. 15, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat an...

Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting

PALO ALTO, Calif., Dec. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and...

Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor Conferences

PALO ALTO, Calif., Nov. 10, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat an...